Yorkshire Lung Screening Trial (YLST): protocol for a randomised controlled trial to evaluate invitation to community-based low-dose CT screening for lung cancer versus usual care in a targeted population at risk

BMJ Open

Volumn 10, Issue 9, 2020, Pages

  Crosbie, Philip Aj ^a   Gabe, Rhian ^b   Simmonds, Irene ^c   Kennedy, Martyn ^d   Rogerson, Suzanne ^d   Ahmed, Nazia ^c   Baldwin, David R ^e   Booton, Richard ^f   Cochrane, Ann ^g   Darby, Michael ^d   Franks, Kevin ^d   Hinde, Sebastian ^g   Janes, Sam M ^h   MacLeod, Una ⁱ   Messenger, Mike ^j   Moller, Henrik ^k   Murray, Rachael L ^l   Neal, Richard D ^c   Quaife, Samantha L ^h   Sculpher, Mark ^g   Tharmanathan, Puvanendran ^g   Torgerson, David ^g   Callister, Matthew Ej ^d   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY OF YORK   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF HULL   (United Kingdom)

^j UNIVERSITY OF LEEDS   (United Kingdom)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF NOTTINGHAM   (United Kingdom)

more..

Author keywords

chest imaging; respiratory tract tumours

Indexed keywords

AGED; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; HUMAN; LUNG; LUNG TUMOR; MIDDLE AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; HUMANS; LUNG; LUNG NEOPLASMS; MIDDLE AGED; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85090818818     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2020-037075     Document Type: Article

References (48)

1. Aberle DR, Adams AM, et al, National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
2. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020;382:503-13.
3. Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the mild trial: new confrmation of lung cancer screening effcacy. Ann Oncol 2019;30:1672.
4. Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US preventive services Task force recommendation. Ann Intern Med 2013;159:411-20.
5. Moyer VA, Force U, U.S. Preventive Services Task Force. Screening for lung cancer: U.S. preventive services Task force recommendation statement. Ann Intern Med 2014;160:330-338-8.
6. Field JK, Devaraj A, Duffy SW, et al. Ct screening for lung cancer: is the evidence strong enough? Lung Cancer 2016;91:29-35.
7. Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369:245-54.
8. Pinsky P F, Berg CD. Applying the National lung screening trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? J Med Screen 2012;19:154-6.
9. Gracie K, Kennedy MPT, Esterbrook G, et al. The proportion of lung cancer patients attending UK lung cancer clinics who would have been eligible for low-dose CT screening. Eur Respir J 2019;54. doi:10.1183/13993003.02221-2018. [Epub ahead of print: 08 Aug 2019].
10. Tammemägi MC, Church TR, Hocking WG, et al. Evaluation of the lung cancer risks at which to screen ever-and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med 2014;11:e1001764.
11. Ten Haaf K, Bastani M, Cao P, et al. A comparative modeling analysis of risk-based lung cancer screening strategies. J Natl Cancer Inst 2020;112:466-79.
12. de Koning HJ, Meza R, Plevritis SK, et al. Benefts and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. preventive services Task force. Ann Intern Med 2014;160:311-20.
13. Tammemägi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer screening. N Engl J Med 2013;368:728-36.
14. Field JK, Duffy SW, Baldwin DR, et al. Uk lung cancer RCT pilot screening trial: baseline fndings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax 2016;71:161-70.
15. Iyen-Omofoman B, Hubbard RB, Smith CJP, et al. The distribution of lung cancer across sectors of society in the United Kingdom: a study using national primary care data. BMC Public Health 2011;11:857.
16. von Wagner C, Baio G, Raine R, et al. Inequalities in participation in an organized national colorectal cancer screening programme: results from the frst 2.6 million invitations in England. Int J Epidemiol 2011;40:712-8.
17. Sutton S, Wardle J, Taylor T, et al. Predictors of attendance in the United Kingdom fexible sigmoidoscopy screening trial. J Med Screen 2000;7:99-104.
18. Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 2008;112:228-42.
19. Gross C P, Filardo G, Mayne ST, et al. The impact of socioeconomic status and race on trial participation for older women with breast cancer. Cancer 2005;103:483-91.
20. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002;20:2109-17.
21. Ali N, Lifford KJ, Carter B, et al. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK lung cancer screening (UKLS) trial. BMJ Open 2015;5:e008254.
22. Balata H, Tonge J, Barber PV, et al. Attendees of Manchester's lung health check pilot express a preference for community-based lung cancer screening. Thorax 2019;74:1176-8.
23. Reuben DB, Bassett LW, Hirsch SH, et al. A randomized clinical trial to assess the beneft of offering on-site mobile mammography in addition to health education for older women. AJR Am J Roentgenol 2002;179:1509-14.
24. Cole SR, Young G P, Byrne D, et al. Participation in screening for colorectal cancer based on a faecal occult blood test is improved by endorsement by the primary care practitioner. J Med Screen 2002;9:147-52.
25. Hewitson P, Ward AM, Heneghan C, et al. Primary care endorsement letter and a patient leafet to improve participation in colorectal cancer screening: results of a factorial randomised trial. Br J Cancer 2011;105:475-80.
26. Cole SR, Smith A, Wilson C, et al. An advance notifcation letter increases participation in colorectal cancer screening. J Med Screen 2007;14:73-5.
27. Libby G, Bray J, Champion J, et al. Pre-notifcation increases uptake of colorectal cancer screening in all demographic groups: a randomized controlled trial. J Med Screen 2011;18:24-9.
28. Sabatino SA, Lawrence B, Elder R, et al. Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: nine updated systematic reviews for the guide to community preventive services. Am J Prev Med 2012;43:97-118.
29. Everett T, Bryant A, Griffn M F, et al. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Rev 2011;5:CD002834.
30. Quaife SL, Ruparel M, Dickson JL, et al. Lung screen uptake trial (LSUT): randomized controlled clinical trial testing targeted invitation materials. Am J Respir Crit Care Med 2020;201:965-75.
31. Hinde S, Crilly T, Balata H, et al. The cost-effectiveness of the Manchester 'lung health checks', a community-based lung cancer low-dose CT screening pilot. Lung Cancer 2018;126:119-24.
32. Snowsill T, Yang H, Griffn E, et al. Low-Dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation. Health Technol Assess 2018;22:1-276.
33. Crosbie PA, Balata H, Evison M, et al. Second round results from the Manchester 'Lung Health Check' community-based targeted lung cancer screening pilot. Thorax 2019;74:700-4.
34. Crosbie PA, Balata H, Evison M, et al. Implementing lung cancer screening: baseline results from a community-based 'Lung Health Check' pilot in deprived areas of Manchester. Thorax 2019;74:405-9.
35. Quaife SL, Ruparel M, Beeken RJ, et al. The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and 'hard-to-reach' patients. BMC Cancer 2016;16:281.
36. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on frst screening CT. N Engl J Med 2013;369:910-9.
37. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
38. Ware J, Kosinski M, Keller SD. A 12-Item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33.
39. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979;300:1242-5.
40. Quaife SL, Marlow LAV, McEwen A, et al. Attitudes towards lung cancer screening in socioeconomically deprived and heavy smoking communities: informing screening communication. Health Expect 2017;20:563-73.
41. Murray RM, Brain K, Britton J, et al. The Yorkshire enhanced stop smoking study (YesS): a protocol for a randomised controlled trial to evaluate the effect of adding a personalised smoking cessation intervention to a lung cancer screening programme. BMJ Open 2020.
42. Callister MEJ, Baldwin DR, Akram AR, et al. British thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax 2015;70 Suppl 2:ii1-54.
43. Horeweg N, van der Aalst CM, Thunnissen E, et al. Characteristics of lung cancers detected by computer tomography screening in the randomized Nelson trial. Am J Respir Crit Care Med 2013;187:848-54.
44. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 1997;16:1017-29.
45. Boutron I, Altman DG, Moher D, et al. Consort statement for randomized trials of nonpharmacologic treatments: a 2017 update and a consort extension for nonpharmacologic trial Abstracts. Ann Intern Med 2017;167:40-7.
46. Brain K, Carter B, Lifford KJ, et al. Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK lung cancer screening trial. Thorax 2017;72:912-8.
47. van der Aalst CM, van den Bergh KAM, Willemsen MC, et al. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. Thorax 2010;65:600-5.
48. Ashraf H, Saghir Z, Dirksen A, et al. Smoking habits in the randomised Danish lung cancer screening trial with low-dose CT: fnal results after a 5-year screening programme. Thorax 2014;69:574-9.